Sabino De Placido

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 729 citations · Full text

Medicine, Oncology, Pharmacology +17

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

Francesco Schettini, Núria Chic, Fara Brasó‐Maristany et al. · npj Breast Cancer · 2021 · 691 citations · Full text

Medicine, Cancer Biology, Oncology +10

Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

Fortunato Ciardiello, Rosa Caputo, Roberto Bianco et al. · PubMed · 2001 · 646 citations

Medicine, Oncology, Pharmacology +17

Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

Massimo Di Maïo, Ciro Gallo, Natasha B. Leighl et al. · Journal of Clinical Oncology · 2015 · 497 citations · Full text

Medicine, Oncology, Cancer Drug Toxicity Management +16

Estrogen Receptor–Positive, Progesterone Receptor–Negative Breast Cancer: Association With Growth Factor Receptor Expression and Tamoxifen Resistance

Grazia Arpino, Heidi L. Weiss, Adrian V. Lee et al. · JNCI Journal of the National Cancer Institute · 2005 · 485 citations · Full text

Medicine, Endocrinology, Oncology +16